Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371278 | 0.77 | ERN1 (0.47) | ALOX15ALOX12ERN1 | |
| SCHEMBL12971238 | 0.77 | TRPA1 (0.38) | ALOX15ERN1POLBMEN1KMT2A | |
| SCHEMBL23953641 | 0.77 | ERN1 (0.44) | ALOX15ERN1 | |
| SCHEMBL16933897 | 0.74 | ALDH1A1 (0.30) | — | |
| SCHEMBL28006166 | 0.74 | SLC22A8 (0.43) | ALOX15ESR1ESR2ERN1TRPA1 | |
| SCHEMBL6560397 | 0.73 | MAOB (0.44) | ALOX15ERN1POLBMEN1KMT2A | |
| SCHEMBL405155 | 0.71 | SLC22A6 (0.41) | ALOX15ERN1 | |
| Ethylene SCHEMBL7787456 | 0.70 | ALOX15 (0.40) | ALOX15ALOX12ESR1ESR2NQO2 | |
| SCHEMBL94834 | 0.69 | ALOX15 (0.43) | ALOX15ALOX12ESR1ESR2NQO2 | |
| SCHEMBL4551394 | 0.69 | ALDH1A1 (0.47) | ALOX15ERN1POLBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | ALOX15 1280/4885ALOX12 981/4885ESR1 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.